Löfgren Sendromunda Kas-iskelet Sistemi Bulgularının Değerlendirildiği Klinik Araştırma

Biz bu çalışmada Löfgren sendromu ile takipli olan hastaların başlangıç eklem bulgularını ve seyrini, eklem bulgularına eşlik eden bulguları tespit etmeyi, kronik ve akut artrit ile seyreden olguların eklem ve laboratuvar bulguları ile kullandıkları ilaçları karşılaştırarak hangi değişkenlerin kronikleşmeyi etkilemiş olabileceğini araştırmayı amaçladık. Çalışmada 3071 hastanın dosyası retrospektif olarak incelenmiş olup 12 Löfgren sendromlu hasta çalışmaya dahil edilmiştir. Hastaların başlangıç klinik ve laboratuvar bulguları hasta dosyalarından, başlangıç görüntüleme tetkikleri "PACS" sisteminden, kas iskelet sistemi bulguları da telefonla veya yüz yüze görüşülerek elde edilmiştir. Katılımcılar akut artrit (

Anahtar Kelimeler:

Eritema nodozum, Löfgren sendromu, Sarkoidoz

Clinical Research Evaluating Musculoskeletal Findings in Löfgren's Syndrome

In this study, we aimed to determine the initial joint findings in Löfgren's syndrome and investigate which variables might have affected chronicity in patients with the drugs they used. Charts of 3071 patients were analyzed retrospectively and 12 patients were included in the study. The initial clinical and laboratory findings of the patients were obtained from the patients charts, the initial imaging with Löfgren syndrome examinations were obtained from the PACS system, and the musculoskeletal system findings were obtained by telephone or face-to-face interview. Participants were divided into 2 groups as acute (

Keywords:

Erythema nodosum, Löfgren's syndrome, Sarcoidosis,

PDF

___

1. Ungprasert P, Crowson CS, Matteson EL. Clinical Characteristics of Sarcoid Arthropathy: A Population-Based Study. Arthritis Care Res (Hoboken) 2016; 68 (5):695-699. doi:10.1002/acr.22737.
2. Brown F, Modi P, Tanner LS. Lofgren Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. 2020 Aug 8.
3. O'Regan A, Berman JS.Sarcoidosis. Ann Intern Med 156 (9) 2012:ITC5-1, ITC5-2, ITC5-3, ITC5-4, ITC5-5, ITC5-6, ITC5-7, ITC5-8, ITC5-9, ITC5-10, ITC15-11, ITC15-12, ITC15-13, ITC15-14, ITC15-15; quiz ITC15-16. doi:10.7326/0003-4819-156-9-201205010-01005.
4. Visser H, Vos K, Zanelli E, et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann Rheum Dis.2002;61 (6):499-504. doi:10.1136/ard.61.6.499.
5. Arthritis in Sarcoidosis G, Agarwal V, Agrawal V, Aggarwal A, Aggarwal P, et al. Arthritis in sarcoidosis: A multicentric study from India. Int J Rheum Dis. 2018;21 (9):1728-1733. doi:10.1111/1756-185X.13349.
6. Kobak S. Sarcoidosis: a rheumatologist's perspective. Ther Adv Musculoskelet Dis 2015;7 (5):196-205. doi:10.1177/1759720X15591310.
7. Mana J, Gomez-Vaquero C, Montero A, Salazar A, et al. Lofgren's syndrome revisited: a study of 186 patients. Am J Med 1999;107 (3):240-245. doi:10.1016/s0002-9343(99)00223-5.
8. Johard U, Eklund A. Recurrent Lofgren's syndrome in three patients with sarcoidosis. Sarcoidosis1993;10 (2):125-127.
9. Kaufman LD. Lofgren's syndrome (acute sarcoidosis) sine erythema nodosum mimicking acute rheumatoid arthritis. N Y State J Med 1990;90 (9):463-464.
10. Griep EN, van Spiegel PI, van Soesbergen RM. Sarcoidosis accompanied by pulmonary tuberculosis and complicated by sacroiliitis. Arthritis Rheum 1993;36 (5):716-721. doi:10.1002/art.1780360521.
11. Sequeira W, Stinar D. Serum angiotensin-converting enzyme levels in sarcoid arthritis. Arch Intern Med 1986;146 (1):125-127.
12. Sejdic A, Graudal N, Baslund B. Clinical and biochemical presentation of sarcoidosis with high and normal serum angiotensin-converting enzyme. Scand J Rheumatol 2018;47 (6):487-490. doi:10.1080/03009742.2017.1420818.
13. Romer FK. Clinical and biochemical aspects of sarcoidosis. With special reference to angiotensin-converting enzyme. Acta Med Scand Suppl 1984;690:3-96.
14. Muthuswamy PP, Lopez-Majano V, Ranginwala M, Trainor WD. Serum angiotensin-converting enzyme activity as an indicator of total body granuloma load and prognosis in sarcoidosis. Sarcoidosis 1984;4 (2):142-148.
15. Zisman DA, Shorr AF, Lynch JP, 3rd. Sarcoidosis involving the musculoskeletal system. Semin Respir Crit Care Med 2002;23 (6):555-570. doi:10.1055/s-2002-36520.
16. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med 1997;18 (4):853-864. doi:10.1016/s0272-5231(05)70423-8.
17. Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn MF, Malaise MG. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995;34 (7):642-644. doi:10.1093/rheumatology/34.7.642.
18. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. (2005) Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum2005;53 (5):788-791. doi:10.1002/art.21468.
19. Kobak S, Sever F, Ince O, Orman M. The prevalence of sacroiliitis and spondyloarthritis in patients with sarcoidosis. Int J Rheumatol 2014:289454. doi:10.1155/2014/289454.